Abiopharma

🔍 Mancini Anthony (Executive)

Company: Revolution Medicines, Inc. (RVMD)

Report Date: 2026-03-25

Detailed Transactions and Holdings:

• Acquired 37,450 shares of Common Stock at $33.62 per share (Direct)
  Date: 2026-03-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 91,850.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,800 shares of Common Stock at $93.223 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 90,050.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 3,128 shares of Common Stock at $94.1561 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 86,922.00 | transaction_form_type: 4 | Footnotes: F1, F4, F2
• Sold 21,086 shares of Common Stock at $95.4859 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 65,836.00 | transaction_form_type: 4 | Footnotes: F1, F5, F2
• Sold 11,036 shares of Common Stock at $96.4299 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,800.00 | transaction_form_type: 4 | Footnotes: F1, F6, F2
• Sold 400 shares of Common Stock at $97.2071 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,400.00 | transaction_form_type: 4 | Footnotes: F1, F7, F2
• Sold 37,450 shares of Stock Option (Right to Buy) at $33.62 per share (Derivative)
  Date: 2026-03-25 | Code: M | Expires: 2035-03-31 | equity_swap_involved: 0 | shares_owned_after: 112,350.00 | transaction_form_type: 4 | Footnotes: F1, F8

Footnotes:

• F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025.
• F2: Includes 54,400 Restricted Stock Units.
• F3: This transaction was executed in multiple trades at prices ranging from $92.69 to $93.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: This transaction was executed in multiple trades at prices ranging from $93.75 to $94.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F5: This transaction was executed in multiple trades at prices ranging from $95.00 to $95.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F6: This transaction was executed in multiple trades at prices ranging from $96.00 to $96.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F7: This transaction was executed in multiple trades at prices ranging from $97.12 to $97.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F8: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
• REMARKS: Chief Global Commercialization Officer